Results from the CD4-driven STACCATO study [11], with re-treatment threshold of CD4+ T cell count <350 cells/μl, suggest that higher CD4+ thresholds may minimize the risks of interrupting ART, although even in that study the interrupting ARM had higher frequency of candidiasis. Here, CD4 is linked to candidiasis.